Drug Use Investigation for Arepanrix® (H1N1)

CompletedOBSERVATIONAL
Enrollment

3,405

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

July 31, 2010

Study Completion Date

October 31, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

Arepanrix®

Injected according to the prescribing information in the locally approved label by the authorities.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02069496 - Drug Use Investigation for Arepanrix® (H1N1) | Biotech Hunter | Biotech Hunter